Pre-Revenue Biotech Companies Cleared to List on Hong Kong Stock Exchange

Published date09 January 2018
Law FirmJones Day
AuthorAlan Seem,Charles Chau,Tony Chen,Joelle Lau
Subject MatterChina,Listing Standards,Disclosure Requirements,Foreign Investment,Revenue Growth,Hong Kong,Listing Rules,Hong Kong Stock Exchange,Research and Development,Technology Sector,Fund-raising

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT